PMVP Stock Rises 19% in 3 Months: Here's What You Need to KnowZacks Investment Research · Oct 12, 2026
PMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer OpportunitySeeking Alpha · Oct 7, 2026
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock Has Consensus Target Price of $4.33 According to AnalystsDefense World · Sep 29, 2026
Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?Zacks Investment Research · Sep 16, 2026
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of SecuritiesGlobeNewsWire · Aug 31, 2026
PMV Pharma Announces Proposed Public Offering of SecuritiesGlobeNewsWire · Aug 31, 2026PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.39 | -$0.34 | Beat |
| May 12, 2026 | -$0.41 | -$0.34 | Beat |
| Mar 6, 2026 | -$0.40 | -$0.34 | Beat |
| Nov 12, 2025 | -$0.40 | -$0.40 | Beat |
| Aug 7, 2025 | -$0.39 | -$0.41 | Miss |
| May 9, 2025 | -$0.37 | -$0.34 | Beat |